ÂÜÀòÂÒÂ×

Fatima Kranc, DPhil has a diverse work experience. Fatima began their career in 2004 as a Career Development Fellow at the Medical Research Council, where they trained in science and developed technical skills in genome editing and analysis. In 2009, they moved to Oxford University Innovation as a Project Manager, where they were responsible for building strategic relationships at the Medical Sciences division and external organisations. In 2010, they became a Project Development Manager for Cancer Research Technology, where they were responsible for all business activities from early stage sourcing to deal execution. In 2013, they moved to Cancer Research UK (CRUK) as a Cancer Research Manager, where they drove collaborations between Centre’s scientists and clinicians to drive lab-based treatments and biomarkers into early phase studies and clinical trials. In 2018, they became a Commercialisation Manager for Babraham Institute Enterprise Ltd, where they identified and commercialised early-stage technologies in the fields of epigenetics, immunology and cell signalling. In 2020, they joined Cambridge Enterprise as an Investment Manager and Senior Investment Associate, where they assisted with team formation, development of business plans, financial modelling and value propositions for pre-seed, seed and series A/B investments. In 2021, they became a Board Observer for CamRegen Limited and a Non-Executive Director for HexagonFab. In 2022, they became a Board Observer for Colorifix Limited and a Non-Executive Director for Semarion.

Fatima Kranc completed their DPhil in Clinical Medicine at the University of Oxford in 2004. Fatima had previously earned their Bachelor's degree in Biology from Universidade do Porto in 2001.